Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 20

Trial readouts

GLP-1 and Amylin Feeding Study in Rats

A rat study found stronger feeding suppression when GLP-1 and amylin receptor pathways were activated together in one brain region.

20 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Iran's GLP-1 Cost-Effectiveness Model

An Iranian 68-week model found semaglutide cost-effective at its threshold, while tirzepatide offered more benefit at a higher estimated cost.

20 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide, Depression and HIV

Depressive-symptom scores were stable overall after semaglutide began in 354 people with HIV, but the uncontrolled study cannot prove psychiatric safety.

20 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Semaglutide and Handgrip Strength

A new systematic review found very low-certainty evidence on handgrip strength after semaglutide, not proof of strength preservation or loss.

20 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

How Oral Semaglutide Enhancers Differ

A preclinical comparison of SNAC, DDM and LLC found distinct intestinal transport and barrier-response patterns for semaglutide.

20 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide vs Revisional Surgery

A retrospective cohort compared semaglutide with revisional bariatric surgery after recurrent weight gain following a primary operation.

20 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

TAB trial: tirzepatide plus buprenorphine

The recruiting TAB trial will test tirzepatide added to buprenorphine for opioid use disorder, but its design paper reports no outcomes.

20 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Tirzepatide and Lithium: A New Case Report

A newly indexed case report links tirzepatide and lithium toxicity, but its accessible record contains no clinical details or evidence of causation.

20 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide in a UK digital cohort

A 630,545-person UK tirzepatide cohort reported substantial weight loss, but missing weights and self-pay selection limit interpretation.

20 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

ADCY4 Atherosclerosis Mouse Study

A laboratory study links endothelial ADCY4 to vascular inflammation and semaglutide effects in cells and mice, not to a new human treatment result.

19 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Drugs and AF in Obesity With CKD

A matched cohort linked GLP-1 receptor agonist use with less one-year atrial fibrillation in non-diabetic adults with obesity and CKD.

19 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Therapies in ESRD: 2026 Meta-Analysis

A 2026 meta-analysis pooled 19 studies and 388 patients with end-stage renal disease, but most treatment-specific estimates concerned semaglutide.

19 Oct 2026 · PeptideMethods Editorial Team · 5 min read